Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

Needham analyst Joseph Stringer has maintained their neutral stance on VRTX stock, giving a Hold rating today.Invest with Confidence: Follow ...

It rose 106% from levels of $220 in early 2022 to $450 now. This can be attributed to: Vertex Pharmaceuticals’ revenue growth has been driven by strong uptake in Trikafta/Kaftrio – a ...

Vertex Pharmaceuticals (VRTX ... In the meantime, our current consensus estimate forecasts the revenue to be $2.77 billion, indicating a 10.22% growth compared to the corresponding quarter ...

Interpreting Analyst Ratings: A Closer Look The perception of Vertex Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts ...

BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...

Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

For the most comprehensive analysis of Vertex Pharmaceuticals, including detailed financial health scores, Fair Value estimates, and expert insights, explore InvestingPro's exclusive research report.